Custom-tailored extrapulmonary lung support - now with new options for communication and flexibility
(PresseBox) - The existing range of the modularly designed system platform of the iLA activve® is further optimized by the current hardware upgrade and the associated features. Novalung's all-rounder for extrapulmonary treatment of lung failure thus covers the full spectrum of extrapulmonary lung support and at the same time facilitates individual and custom-tailored therapy.
Two years ago, Novalung successfully launched the pump-driven lung support system iLA activve® on the market, thereby taking into account the developments in the ever-expanding application areas of extrapulmonary lung support.
The iLA activve® system consists of perfectly matched modular components: the iLA activve® Console, the iLA activve® Membrane Ventilators, the unique iLA activve® Pump and the powerful NovaTherm® Heater / Cooler. Ultimately, the system is conveniently assembled on the iLA activve® Trolley and can be used for a wide range of indications and applications in neonates, children and adults.
The new iLA activve® system offers additional features in the field of communication and flexibility. Existing consoles can be easily retrofitted with the new hardware upgrade. The PDMS data interface of the new iLA activve®
Console enables seamless integration into a patient-related electronic documentation system. Via connection to Philips IntelliVue®, therapy data can be integrated directly into an external Philips monitoring system. The nurse call interface enables alarms of the iLA activve® Console to catch attention. In addition, new high-capacity batteries guarantee independent operation of the console for at least 120 and up to more than 420 minutes.
iLA activve® System Platform: From efficient carbon dioxide removal to complete oxygen supply, with the reliability of a closed system.
Novalung GmbH is a leading international medical device company with headquarters in Heilbronn, Germany. Novalung has been developing and manufacturing products for interventional lung assist (iLA®) therapy in Germany since 2003 and is today the first to offer a complete product portfolio for extrapulmonary lung support. Whatever form of extrapulmonary lung support is required, Novalung can offer the perfect solution, from effective removal of carbon dioxide to complete oxygenation support, for new-born infants through to adults. A broad technology base, extensive clinical experience, specialized know-how and outstanding motivation guarantee the consistently high quality of Novalung products. Working together with leading users, the company has continuously advanced Novalung's technologies to develop iLA® therapy as an alternative to invasive ventilation, and as such has initiated a paradigm shift in the treatment of lung failure.
Following a clear focus on the further development of iLA® therapy to pioneer novel solutions for acute and chronic lung failure, the company remains on track for continued expansion.
From our manufacturing sites across Germany we deliver solutions for lung failure throughout the world. For more information, please visit:
www.novalung.com.
Novalung GmbH is a leading international medical device company with headquarters in Heilbronn, Germany. Novalung has been developing and manufacturing products for interventional lung assist (iLA®) therapy in Germany since 2003 and is today the first to offer a complete product portfolio for extrapulmonary lung support. Whatever form of extrapulmonary lung support is required, Novalung can offer the perfect solution, from effective removal of carbon dioxide to complete oxygenation support, for new-born infants through to adults. A broad technology base, extensive clinical experience, specialized know-how and outstanding motivation guarantee the consistently high quality of Novalung products. Working together with leading users, the company has continuously advanced Novalung's technologies to develop iLA® therapy as an alternative to invasive ventilation, and as such has initiated a paradigm shift in the treatment of lung failure.
Following a clear focus on the further development of iLA® therapy to pioneer novel solutions for acute and chronic lung failure, the company remains on track for continued expansion.
From our manufacturing sites across Germany we deliver solutions for lung failure throughout the world. For more information, please visit:
www.novalung.com.
Datum: 05.08.2014 - 17:28 Uhr
Sprache: Deutsch
News-ID 334791
Anzahl Zeichen: 3236
contact information:
Town:
Heilbronn
Kategorie:
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Custom-tailored extrapulmonary lung support - now with new options for communication and flexibility"
steht unter der journalistisch-redaktionellen Verantwortung von
Novalung GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
